Mario Boccadoro

TL;DR: Thalidomide may have been the precipitating factor of DVT in the authors' patient with SLE who had predisposing factors for DVT, however in a prothrombotic condition as BD the treatment with thalidomides has not been associated with thrombosis, and a clear relationship between increased incidence of thROMbotic events and thalidmide therapy in non-malignant conditions has not yet clearly been demonstrated.

TL;DR: DARA, a human, CD38-targeting, IgGκ monoclonal antibody, is approved in many countries for use as monotherapy in relapsed/refractory MM (RRMM), and in combination with standard-of-care drugs.

TL;DR: In patients treated with new drugs the detrimental effect of extramedullary disease at diagnosis is limited, that lenalidomide is effective as are proteasome inhibitors, and that these patients tend to acquire a more aggressive disease in later stages.

TL;DR: The availability of different chemotherapeutic options requires particular attention to treatment strategies applied to specific disease phases and patient conditions, as well as emphasis on clinical trials promising substantial future gain.

TL;DR: The data indicate that the combination ofIFN‐α plus IFN‐γ and DEX are the strongest inhibitors of both BrdUrd uptake and secretion, and their combined use could be considered as a possible new treatment strategy.